Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
29 juil. 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Global Regenerative Medicine Partnering Deal Terms and Agreements Report 2021: Access to Deals and Contract Documents for 1450+ Deals
21 juil. 2021 05h28 HE
|
Research and Markets
Dublin, July 21, 2021 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.com's offering. The Global...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results
15 juil. 2021 19h27 HE
|
Cryo-Cell International, Inc.
OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store...
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
23 juin 2021 16h01 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Global Bio-Pharma Logistics Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts
09 juin 2021 09h49 HE
|
Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Bio-Pharma Logistics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering....
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
19 mai 2021 17h02 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cryo-Cell International Proudly Announces Two Ongoing COVID-19 Related Trials
10 mai 2021 09h00 HE
|
Cryo-Cell International, Inc.
MIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell’s Medical Director, Dr. Joanne Kurtzberg and her research team at The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2021 Financial Results
14 avr. 2021 18h14 HE
|
Cryo-Cell International, Inc.
OLDSMAR, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store...
Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End Users and Geographical Regions
01 avr. 2021 05h53 HE
|
Research and Markets
Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions:...
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
15 mars 2021 07h39 HE
|
Rubius Therapeutics
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells into...